Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
ACTIVE_NOT_RECRUITING
Status
Conditions
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Double-Expressor Lymphoma
- EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
- Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Bone Marrow Biopsy
- PROCEDURE: Computed Tomography
- DRUG: Cyclophosphamide
- DRUG: Doxorubicin Hydrochloride
- DRUG: Etoposide
- PROCEDURE: Lumbar Puncture
- PROCEDURE: Positron Emission Tomography
- DRUG: Prednisone
- BIOLOGICAL: Rituximab
- DRUG: Venetoclax
- DRUG: Vincristine Sulfate
Sponsor
National Cancer Institute (NCI)